Lilly faces conflict questions over Oura telehealth deal; DEA clears narcolepsy pill

Eli Lilly is under scrutiny for a potential conflict of interest involving Oura's acquisition of a telehealth company, raising governance concerns. Separately, the DEA approved a narcolepsy treatment, marking a regulatory milestone. The conflict issue could affect Lilly's reputation and regulatory standing, while the DEA approval is a positive for the company's pipeline.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works